A synthetic peptide derived from rattlesnake venom lowered blood pressure and improved kidney filtration in rats with chronic kidney disease through a nitric oxide-mediated mechanism.
70% structural homologyNPCdc shares 70% structural similarity with natriuretic peptides found across species including humans, supporting its therapeutic potential
What the researchers found
The synthetic natriuretic peptide NPCdc, derived from rattlesnake venom, decreased mean arterial pressure and NADPH oxidase activity while increasing glomerular filtration rate, fractional sodium excretion, and nitric oxide levels in both control and nephrectomized rats. These effects were mediated through nitric oxide and components of natriuretic peptide receptor C (NPR-C) signaling, specifically involving ERK1/2 phosphorylation at Thr-202/Tyr-204.
The peptide was infused at 7.5 μg/kg/min for 70 minutes, producing beneficial cardiovascular and renal effects even in rats with reduced kidney mass (5/6 nephrectomy), suggesting potential therapeutic application for cardiorenal syndrome.
Why it matters
Cardiorenal syndrome — where heart and kidney failure worsen each other — is a major clinical challenge with limited treatment options. This venom-derived synthetic peptide simultaneously lowered blood pressure and improved kidney filtration, addressing both the cardiovascular and renal components. Its novel mechanism through NPR-C signaling, rather than the conventional natriuretic peptide receptors A and B, opens a new therapeutic pathway.
The numbers in context
7.5 μg/kg/min dose · 70 min infusion · 70% structural homology with human natriuretic peptides · 5/6 nephrectomy model
How the study worked
Anesthetized Wistar rats were divided into sham-operated controls and 5/6 nephrectomy groups. Each group received either saline or NPCdc infusion at 7.5 μg/kg/min for 70 minutes. Researchers measured arterial pressure, glomerular filtration rate, sodium excretion, nitric oxide levels, NADPH oxidase activity, and phosphorylation of several signaling proteins.
Who was studied
Wistar rats (sham-operated controls and 5/6 nephrectomy model of chronic kidney disease)
What this study cannot tell us
This was an animal study in anesthetized rats, so results may not directly translate to humans. The acute 70-minute infusion does not reveal long-term effects or safety. The 5/6 nephrectomy model simulates chronic kidney disease but does not fully replicate human cardiorenal syndrome.
How to read the evidence
This is a preclinical animal study using an established rat model of chronic kidney disease. While the results are mechanistically detailed and promising, human studies are needed before clinical relevance can be confirmed.
When this study was published
Published in 2020, this study represents relatively recent preclinical work. Follow-up studies may have advanced this peptide toward further development.
The bigger picture
Nature has long been a source of drug inspiration, and venom-derived peptides are an active area of pharmaceutical research. This work adds to growing evidence that synthetic versions of venom peptides can be engineered to have therapeutic properties while avoiding toxicity. The dual cardiovascular-renal benefit is particularly valuable given the limited treatment options for cardiorenal syndrome.
Questions still open
- Would NPCdc remain effective and safe during chronic long-term administration rather than a single 70-minute infusion?
- Can this peptide be modified for oral or subcutaneous delivery rather than continuous intravenous infusion?
- How does NPCdc compare to existing natriuretic peptide therapies like nesiritide in terms of renal protective effects?
Common questions
What is NPCdc and where does it come from?
What is cardiorenal syndrome?
Read the original research
NO mediates the effect of the synthetic natriuretic peptide NPCdc on kidney and aorta in nephrectomised rats.
European journal of pharmacology, 866, 172780
Citation
Aires, Regina S; Vieira, Leucio D; Freitas, Ana C N; de Lima, Maria E; Lima, Natalia K S; Farias, Juliane S; Paixão, Ana D. (2020). NO mediates the effect of the synthetic natriuretic peptide NPCdc on kidney and aorta in nephrectomised rats.. European journal of pharmacology, 866, 172780. https://doi.org/10.1016/j.ejphar.2019.172780